Healthcare Equipment and Supplies
Company Overview of Tethys Bioscience, Inc.
Tethys Bioscience, Inc., a cardiometabolic diagnostics company, develops and commercializes biomarker-based blood tests that predict imminent disease risk and enable targeted intervention to preempt the onset of chronic conditions. Its portfolio includes PreDx Diabetes Risk Score, a blood test that combines multiple blood-borne markers and an algorithm to deliver the risk stratification for patients at risk for type 2 diabetes; Reduce My Risk Diabetes Prevention Initiative, an educational program targeted to individuals who are at high risk for type 2 diabetes but have not yet developed the disease; and PreDx test, a multi-biomarker blood test used for the stratification and monitoring of pr...
5858 Horton Street
Emeryville, CA 94608
Founded in 2005
Key Executives for Tethys Bioscience, Inc.
Chief Executive Officer and President
Senior Vice President of Marketing
Compensation as of Fiscal Year 2014.
Tethys Bioscience, Inc. Key Developments
Tethys Bioscience Is Reportedly Up For Sale
Nov 4 13
Tethys Bioscience, Inc. is up for sale. Tethys BioScience is shutting down after failing to win approval for Medicaid reimbursements for its diabetes tests, Fortune's Dan Primack reported. He added that company investors are now looking for buyers for the company's assets.
Tethys Bioscience, Inc. Announces PreDx Test Now Available With Finger Stick Collection Method
May 28 13
Tethys Bioscience has announced that the PreDx test, a multi-biomarker blood test used for the stratification and monitoring of prediabetes patients, can now be performed using capillary blood collected via a simple finger stick procedure. The PreDx test measures seven biomarkers implicated in the development of type 2 diabetes, and utilizes a proprietary algorithm to generate a 'personalized' numerical score that ranks a prediabetic's 5-year risk of progression to diabetes on a scale of 1 to 10, with a higher score indicating a higher 5-year risk of progression. Baseline scores are used to stratify prediabetes patients into low, moderate or high- risk categories for disease progression, then retesting is used to monitor changes in the patient's score, which reflect the efficacy of preventive interventions in reducing the patient's level of risk.
Tethys Bioscience, Inc. Presents at 25th Annual ROTH Conference, Mar-20-2013 10:30 AM
Mar 15 13
Tethys Bioscience, Inc. Presents at 25th Annual ROTH Conference, Mar-20-2013 10:30 AM. Venue: The Ritz-Carlton, 1 Ritz Carlton Drive, Dana Point, Laguna Niguel, California, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|